Click here for slides on this topic


C-peptide

A by-product of insulin production. Plasma C-peptide has a longer half-life than insulin and is often used to provide an indication of endogenous insulin secretion.


The following content matched the glossary term: C-peptide

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

A clinical trial to maintain glycemic control in youth with type 2 diabetes

Top

TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. Epub ahead of print.The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study was a multicenter, randomized clinical trial that examined whether rosiglitazone plus metformin or intensive lifestyle intervention plus metformin initiated early in the disease course of youth-onset type 2 diabetes would maintain acceptable glycemic control better than metformin monotherapy.

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Top

Horowitz M, Flint A, Jones KL, et al. Effect of the once daily human GLP 1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012 Mar 23. Epub ahead of print. Liraglutide reduces bodyweight in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the mechanisms underlying this effect.

Effects of glucagon-like peptide-1 receptor agonists on weight loss

Top

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771. Vilsbøll and colleagues conducted a meta-analysis and systematic review of trials to analyze the risks and benefits of GLP-1 receptor agonists among overweight or obese subjects with type 2 diabetes.

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment

Top

Nowicki M, Rychlik I, Haller H, et al. Int J Clin Pract . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. 2011;65(12):1230-1239. Nowicki and colleagues examined the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, saxagliptin, among patients with inadequately controlled type 2 diabetes and renal impairment in a 52-week study.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting systematic review and meta analysis. BMJ. 2012;344:e1369. doi 10.1136 bmj.e1369. OBJECTIVE: To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

Top

Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once weekly glucagon like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78. OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: C-peptide Slides Found: 90
Energy Balance: Afferent and Efferent Signals
Acute Effect of Peptide YY3-36 on Food Intake
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Glucagon-Like Peptide-1
Insulin and GLP-1 Responses to Meals
GLP-1 Release Is Reduced in Type 2 Diabetes
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Exenatide: Effect on the Beta-Cell
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Beta-Cell Adaptation to Insulin Resistance: Longitudinal Data in Normal Women
Functional Defects in beta-Cells in the Development of Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Vildagliptin vs Metformin: A1C
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
TODAY Study: Eligibility Criteria and Run-in Period
DURATION-6: Design
DURATION-6: Secondary Endpoints
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
Diabetes Surgery Study: Design
GLP-1 Receptor Agonists: Dosage Adjustment by Degree of Renal Impairment
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
Liraglutide 12-Week Treatment: Effect on Glycemic Control
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Improves ß-Cell Function and Insulin Secretion During Hyperglycemia in Patients With Type 2 Diabetes
Liraglutide Enhances Glucose-Dependent Insulin Secretion
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
Type 1 Diabetes Classification & Diagnosis
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Diabetes Guidelines Pharmacologic Therapy for Older Adults | NDEI
Preoperative Workup Metabolic Surgery for Type 2 Diabetes Treatment | NDEI